/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
Dr Brian Halliday is a consultant cardiologist at Royal Brompton and Harefield hospitals and a clinical senior lecturer and British Heart Foundation intermediate fellow at the National Heart and Lung Institute, Imperial College London. In his clinical practice, he looks after patients with all forms of cardiomyopathy and reports cardiovascular magnetic resonance. Dr Halliday's research interests focus on improving the treatment of patients with dilated cardiomyopathy at different stages of disease. He designed and conducted the British Heart Foundation (BHF)-funded TRED-HF trial and was first author of the primary publication in The Lancet. More recently he has received further funding from the BHF to perform a follow-on trial in patients with recovered dilated cardiomyopathy (TRED-HF-2), as well as a trial of a novel antioxidant (MitoQ) in patients with persistent dilated cardiomyopathy, as part of his BHF Intermediate Fellowship
